These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 25927667)
1. Transarterial chemoembolization is ineffective for neuroendocrine tumors metastatic to the caudate lobe: a single institution review. Shirley LA; McNally M; Chokshi R; Jones N; Tassone P; Guy G; Khabiri H; Schmidt C; Shah M; Bloomston M World J Surg Oncol; 2015 May; 13():167. PubMed ID: 25927667 [TBL] [Abstract][Full Text] [Related]
2. Extrahepatic disease should not preclude transarterial chemoembolization for metastatic neuroendocrine carcinoma. Arrese D; McNally ME; Chokshi R; Feria-Arias E; Schmidt C; Klemanski D; Gregory G; Khabiri H; Shah M; Bloomston M Ann Surg Oncol; 2013 Apr; 20(4):1114-20. PubMed ID: 23456380 [TBL] [Abstract][Full Text] [Related]
3. Neutrophil Lymphocyte Ratio and Transarterial Chemoembolization in Neuroendocrine Tumor Metastases. McDermott SM; Saunders ND; Schneider EB; Strosberg D; Onesti J; Dillhoff M; Schmidt CR; Shirley LA J Surg Res; 2018 Dec; 232():369-375. PubMed ID: 30463743 [TBL] [Abstract][Full Text] [Related]
4. Initial Treatment of Unresectable Neuroendocrine Tumor Liver Metastases with Transarterial Chemoembolization using Streptozotocin: A 20-Year Experience. Dhir M; Shrestha R; Steel JL; Marsh JW; Tsung A; Tublin ME; Amesur NB; Orons PD; Santos E; Geller DA Ann Surg Oncol; 2017 Feb; 24(2):450-459. PubMed ID: 27663565 [TBL] [Abstract][Full Text] [Related]
5. Transarterial Chemoembolization for Metastatic Neuroendocrine Tumors With Massive Hepatic Tumor Burden: Is the Benefit Worth the Risk? Kitano M; Davidson GW; Shirley LA; Schmidt CR; Guy GE; Khabiri H; Dowell JD; Shah MH; Bloomston M Ann Surg Oncol; 2016 Nov; 23(12):4008-4015. PubMed ID: 27393568 [TBL] [Abstract][Full Text] [Related]
6. Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors. Fiore F; Del Prete M; Franco R; Marotta V; Ramundo V; Marciello F; Di Sarno A; Carratù AC; de Luca di Roseto C; Colao A; Faggiano A Endocrine; 2014 Sep; 47(1):177-82. PubMed ID: 24385266 [TBL] [Abstract][Full Text] [Related]
8. Transcatheter arterial chemoembolization (TACE) for lymph node metastases in patients with hepatocellular carcinoma. Wu H; Liu S; Zheng J; Ji G; Han J; Xie Y J Surg Oncol; 2015 Sep; 112(4):372-6. PubMed ID: 26368066 [TBL] [Abstract][Full Text] [Related]
9. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Osborne DA; Zervos EE; Strosberg J; Boe BA; Malafa M; Rosemurgy AS; Yeatman TJ; Carey L; Duhaine L; Kvols LK Ann Surg Oncol; 2006 Apr; 13(4):572-81. PubMed ID: 16511671 [TBL] [Abstract][Full Text] [Related]
10. Intra-arterial hepatic chemoembolization in liver metastases from neuroendocrine tumors: a phase II study. Fiorentini G; Rossi S; Bonechi F; Vaira M; De Simone M; Dentico P; Bernardeschi P; Cantore M; Guadagni S J Chemother; 2004 Jun; 16(3):293-7. PubMed ID: 15330328 [TBL] [Abstract][Full Text] [Related]
11. Repetitive transarterial chemoembolization (TACE) of liver metastases from gastric cancer: local control and survival results. Vogl TJ; Gruber-Rouh T; Eichler K; Nour-Eldin NE; Trojan J; Zangos S; Naguib NN Eur J Radiol; 2013 Feb; 82(2):258-63. PubMed ID: 23127803 [TBL] [Abstract][Full Text] [Related]
12. Prognostic Impact of Serum Pancreastatin Following Chemoembolization for Neuroendocrine Tumors. Strosberg D; Schneider EB; Onesti J; Saunders N; Konda B; Shah M; Dillhoff M; Schmidt CR; Shirley LA Ann Surg Oncol; 2018 Nov; 25(12):3613-3620. PubMed ID: 30182331 [TBL] [Abstract][Full Text] [Related]
13. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Gupta S; Johnson MM; Murthy R; Ahrar K; Wallace MJ; Madoff DC; McRae SE; Hicks ME; Rao S; Vauthey JN; Ajani JA; Yao JC Cancer; 2005 Oct; 104(8):1590-602. PubMed ID: 16134179 [TBL] [Abstract][Full Text] [Related]
14. Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference. Kennedy A; Bester L; Salem R; Sharma RA; Parks RW; Ruszniewski P; HPB (Oxford); 2015 Jan; 17(1):29-37. PubMed ID: 25186181 [TBL] [Abstract][Full Text] [Related]
15. Transarterial chemoembolization for liver metastases of a pancreatic neuroendocrine neoplasm: a single-center experience. Nanno Y; Toyama H; Ueshima E; Sofue K; Matsumoto I; Ishida J; Urade T; Fukushima K; Gon H; Tsugawa D; Komatsu S; Kuramitsu K; Goto T; Asari S; Yanagimoto H; Kido M; Ajiki T; Fukumoto T Surg Today; 2023 Dec; 53(12):1396-1400. PubMed ID: 37355500 [TBL] [Abstract][Full Text] [Related]
16. Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors--a retrospective single-center analysis. Kress O; Wagner HJ; Wied M; Klose KJ; Arnold R; Alfke H Digestion; 2003; 68(2-3):94-101. PubMed ID: 14593235 [TBL] [Abstract][Full Text] [Related]